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Abstract: The purpose of this study was to develop a novel, highly water-soluble 
poly(L-γ-glutamyl-glutamine)-paclitaxel nanoconjugate (PGG-PTX) that would improve the 
therapeutic index of paclitaxel (PTX). PGG-PTX is a modification of poly(L-glutamic acid)-
paclitaxel conjugate (PGA-PTX) in which an additional glutamic acid has been added to each 
glutamic side chain in the polymer. PGG-PTX has higher water-solubility and faster   dissolution 
than PGA-PTX. Unlike PGA-PTX, PGG-PTX self-assembles into nanoparticles, whose size 
remains in the range of 12–15 nm over the concentration range from 25 to 2,000 µg/mL in 
saline. Its critical micellar concentration in saline was found to be ∼25 µg/mL. The potency of 
PGG-PTX when tested in vitro against the human lung cancer H460 cell line was   comparable to 
other known polymer-PTX conjugates. However, PGG-PTX possesses lower toxicity   compared 
with PGA-PTX in mice. The maximum tolerated dose of PGG-PTX was found to be 350 mg 
PTX/kg, which is 2.2-fold higher than the maximum tolerated dose of 160 mg PTX/kg reported 
for the PGA-PTX. This result indicates that PGG-PTX was substantially less toxic in vivo than 
PGA-PTX.
Keywords: nanoconjugates, poly(L-glutamic acid), poly(L-γ-glutamyl-glutamine)-paclitaxel, 
nanoparticles, anticancer
Introduction
Due to the high cost and uncertain success of new drug development,1 serious effort is 
being devoted to developing novel formulations that can improve the therapeutic ratio 
of established hydrophobic drugs.2,3 Conjugation of such drugs to polymers is one of 
the means of increasing water-solubility. The concepts underlying the development 
of polymer–drug conjugates are not new and have been comprehensively reviewed.4,5 
The core principle is that when a poorly soluble drug is linked to a water-soluble 
  polymer, it results in a conjugate with a markedly improved aqueous solubility that also 
has a prolonged plasma half-life6 and is passively accumulated in solid tumor tissues 
via the “enhanced permeability and retention” effect.6,7 Since the earliest   studies of 
  polymer–drug conjugates in 1975,8 many groups have investigated the use of polymers 
for drug delivery, but only a few polymers, such as N-(2-hydroxypropyl)methacryl-
amide, poly(L-glutamic acid) (PGA), and polyethylene glycol, have been systemically 
examined or have entered clinical trials.4,5 However, none of these polymer conjugates 
have been reported to form nanoparticles in aqueous solutions.   Encapsulation is another 
means of solubilizing hydrophobic anticancer drugs.   Polymeric micelles comprising 
block hydrophilic polyethylene glycol and hydrophobically modified poly-aspartate, 
poly-glutamate, or poly(d,l-lactide) have been used for encapsulating hydrophobic International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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drugs. These are capable of forming nanoparticles when 
loaded with paclitaxel (PTX),9–12 doxorubicin,13,14 and 
cisplatin.15–17
The goal of the study reported here was to design a 
nonblock polymer capable of supporting high drug   loading 
and forming a nanoparticle in aqueous environments. 
We reasoned that the addition of an amino acid between the 
polyglutamic acid and a hydrophobic PTX would provide 
enough flexibility and water-solubility for the conjugate 
to spontaneously self-assemble into a nanoparticle. After 
an optimal amino acid was selected, poly(L-γ-glutamyl-
glutamine) (PGG) was synthesized and conjugated with a 
known hydrophobic drug and its solubility experimentally 
determined. Finally, its in vitro efficacy was examined and 
compared with that of other known polymer–drug conjugates. 
We report here the success of this approach that has important 
implications for the design of polymer–drug conjugates with 
increased therapeutic effectiveness.
Experimental procedures
Materials
PGA, sodium salt, anhydrous N,N-dimethylformamide, 
sodium bicarbonate, and 4-dimethylaminopyridine were 
purchased from Sigma Chemical Co (St Louis, MO). N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide, L-glutamic 
acid di-tert-butyl ester hydrochloride, and   trifluoroacetic 
acid were purchased from EMD Biosciences (La Jolla, 
CA). 1-hydroxybenzotriazole was purchased from Spec-
trum (  Gardena, CA). PTX was purchased from NuBlocks 
(Vista, CA). All the chemicals and reagents were used as 
received without   further purification. 1H-nuclear magnetic 
resonance (1H-NMR) spectra were recorded at 400 MHz 
with a Jeol spectrometer at room temperature. 1H chemical 
shifts are reported in parts per million (ppm).
Size exclusion chromatography–high pressure   liquid 
  chromatography (SEC-HPLC) was operated using a 
  ChemStation program with Agilent 1200 analytical series 
(  Quantum Analytics, Inc; Foster city, CA). The column was 
a Shodex OHpak SB 804HQ (Phenomenex;   Torrance, CA) 
with guard column SB-G 605038. The mobile phase was 
phosphate buffer solution (50 mM phosphate, 50 mM sodium 
chloride [NaCl], 200 ppm sodium azide; pH 6.6) and 45% 
methanol (  HPLC-grade) by volume to volume. The injection 
volume was 10 µL; the column was eluted isocratically at a 
flow rate of 0.525 mL/min over 40 minutes, and the eluate 
monitored with a   multiwavelength detector at 228 nm.
A gel permeation chromatography with multiangle light 
scattering (GPC-MALS) detector was operated using a 
ChemStation program with Agilent 1200 analytical series 
and ASTRA V program with Dawn Heleos light scattering 
detector and refractive index detector (Wyatt   Technology 
  Corporation; Santa Barbara, CA). The   column was Shodex 
OHpak SB 804HQ (Phenomenex) with a guard column SB-G 
605038. The mobile phase was phosphate buffer solution 
(50 mM phosphate, 50 mM NaCl, 200 ppm sodium azide; 
pH 6.6) and 20%–50% methanol (  HPLC-grade) by volume 
to volume. The injection volume was 100 µL, and the elution 
was isocratic at a flow rate of 0.7 mL/min over 60 minutes 
with detection at 228 nm.
Ultraviolet spectra were recorded on a PerkinElmer 
Lambda Bio 40 spectrophotometer (PerkinElmer; Fremont, 
CA). The content of conjugated PTX was   estimated using 
an established method6 based on a standard curve generated 
with known concentrations of PTX in   methanol (A = 228 nm) 
with the R2 value of 0.9999.
Particle size measurements were carried out on the 
  Zetasizer ZS (Malvern Instruments, Malvern, UK). 
Poly(L-γ-glutamyl-glutamine)-paclitaxel conjugate (PGG-
PTX) was first dissolved in 0.9% NaCl at 2 mg/mL. The 
solution was further diluted with 0.9% NaCl to produce a 
series of diluted solutions, which were measured for their 
particle sizes using dynamic light scattering method.
Synthesis of poly(L-glutamic acid)-
paclitaxel conjugates (PGA-PTX)
Poly(L-glutamate) was purchased from Sigma   Chemical Co. 
Its average molecular weight (Mw) reported based on GPC-
MALS is shown in Table 1. Synthesis of PGA-PTX was carried 
out   according to the   procedure reported in the literature6 except 
for the   replacement of 1,3-dicyclohexylcarbodiimide coupling 
agent with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
coupling agent for the ease of purification and to avoid contact 
Table 1 Characteristics of the PGA and PGG polymers and the 
PGG-PTX
Polymers/conjugates PGA35k
a,b PGGb PGG-PTXb
Dn/dc 0.176 ± 004 0.181 ± 0.001 0.173 ± 0.003
Mw (Da) 24,880 ± 170 53,180 ± 270 129,400 ± 1,200
Mw/Mn 1.69 ± 0.01 1.46 ± 0.01 1.87 ± 0.002
Mobile phase PBS + 30% 
MeOH
PBS + 30%  
MeOH
PBS + 45%  
MeOH
Notes: dn/dc is how much the refractive index of a solution varies for a given 
increment in concentration.  aPGA35k was purchased from Sigma Chemical Co. 
Their  certificate  of  analysis  reported  that  its  relative  average  Mw  by  viscosity 
was 35,600 Da and Mw by multiangle light scattering was 22,890 Da; bThe results 
reported here are based on multiangle light scattering.
Abbreviations:  PGA,  poly(l-glutamic  acid);  PGG,  poly(l-γ-glutamyl-glutamine); 
PGG-PTX,  poly(l-γ-glutamyl-glutamine)-paclitaxel  nanoconjugate;  Mw,  molecular 
weight; PBS, phosphate-buffered saline; MeOH, methanol.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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with chloroform. The PTX content of PGA-PTX was about 
32%.
Synthesis of PGG
Poly-L-glutamate sodium salt (relative molecular mass 
35,000, 10.0 g, 0.066 mol/monounit of   polymer) was 
added to a 1000-mL, round-bottom glass flask equipped 
with a teflon   magnetic stir bar and a septum under argon 
  atmosphere. L-glutamic acid di-tert-butyl ester   hydrochloride 
(38.3 g, 0.148 mol), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (37.0 g, 0.193 mol), 1-hydroxybenzotriazole 
(10.6 g, 0.074 mol), and anhydrous N,N-dimethylformamide 
(500 mL) were added to the flask. The mixture solution was 
stirred at room temperature for 24 hours. The reaction   mixture 
solution was poured slowly into the distilled water (3 L) 
while stirring. A white precipitate formed. The   precipitate 
was filtered and washed with water (3 × 250 mL). It was 
then dried under vacuum for 15 hours. All the dried solids 
were transferred to a 1000-mL, round-bottom glass flask 
equipped with a teflon magnetic stir bar and a septum under 
argon atmosphere. Trifluoroacetic acid was added into the 
flask, and the reaction solution was stirred for 5 hours at 
room temperature. Trifluoracetic acid was later removed by 
rotary evaporation. Water (800 mL) was added into the flask, 
and the mixture solution was stirred for 30 minutes until the 
solid became completely dissolved. The solution was poured 
into the dialyzed bags (Mw cut off at 10,000 Da), and PGG 
was dialyzed against water for 24 hours, including changing 
water (4 L) 4 times (once every hour for 3 hours and once 
overnight). The solution was then filtered through a 0.45 µm 
filter and PGG was lyophilized. The obtained PGG (14.8 g) 
was characterized using 1H-NMR, GPC-MALS detector, and 
SEC-HPLC. 1H-NMR (400 MHz, D2O): d 4.40 (br, 1H), 4.22 
(br, 1H), 2.45 (br, 4H), 2.15 (br, 3 H), 1.97 (br, 1 H) ppm. 
GPC-MALS: Zimm Model was used for Mw determination; 
Mw, 53,180 (0.5%); Mw/Mn, 1.46; 94.7% recovery.
Synthesis of PGG-PTX
PGG (10.0 g, 0.063 mol/monomer-unit of polymer) was 
added into a 1000-mL glass flask equipped with a teflon 
magnetic stir bar and a septum under argon atmosphere. 
Anhydrous N,N-dimethylformamide (500 mL) was added 
into the flask, and the solution was stirred at room tem-
perature for an hour to allow complete dispersion. N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (9.4 g, 
0.049 mol) and 4-  dimethylaminopyridine (2.6 g) were added 
to the   solution, and the mixture solution was stirred at room 
  temperature for 15 minutes to allow complete dispersion. 
PTX (5.4 g, 0.0063 mol) was added to the mixture solution, 
and the reaction solution was stirred for 24–28 hours until the 
PTX was unable to be detected by thin layer chromatography 
([TLC], 100% ethyl acetate). The solution was poured slowly 
into 0.2 M aqueous hydrochloric acid solution (1.5 L) while 
  vigorously stirring. A white precipitate formed. The   precipitate 
was isolated by centrifuging the solution for 10 minutes 
at 5,000 rpm. The residue was dissolved in 0.5 M sodium 
bicarbonate solution (1.5 L). PGG-PTX was dialyzed against 
water for 24 hours, including changing water (4 L) 4 times 
(once every hour for 3 hours and once overnight). The solution 
was then filtered through the 0.45 µm filter and lyophilized. 
PGG-PTX (14.7 g) was obtained and characterized using 
GPC-MALS detector and SEC-HPLC. The PTX content was 
determined to be 35.8% by the ultraviolet-visible method.6 
GPC-MALS: Zimm Model was used for Mw determination: 
Mw, 129,400 (0.9%); Mw/Mn: 1.87; 97.7% recovery.
Determination of in vitro cytotoxicity  
and in vivo toxicity
NCI-H460 cells were purchased from American Type Cul-
ture Collection (ATCC HTB 177; Rockville, MD) and were 
grown in Dulbecco’s modified Eagle’s medium with 10% fetal 
bovine serum and 100 U/mL penicillin at 37°C in 5% CO2. 
Relative in vitro cytotoxicity was assessed using the tetra-
zolium reduction assay reported by Monks et al18 Relative 
in vivo toxicity was assessed by determining the maximum 
tolerated dose defined on the basis of a 15% reduction in 
weight. Nude mice (6–8 week old, body weight 21–25 g) 
were purchased from Charles River Lab (Willington, MA). 
PGG-PTX was dissolved in saline at 50 mg per mL and 
administered as an intravenous bolus. Stock solutions were 
prepared fresh on the day of injection.
Results and discussion
Design and synthesis of PGG-PTX
PGA-PTX (also known as CT-2103) was reported to   produce 
complete regression of established tumors in mice6 and has 
demonstrated activity in Phase I19,20 and Phase II21 clinical 
trials. However, the combination of CT-2103 and carboplatin 
was not superior to PTX and carboplatin in a randomized 
Phase III trial in patients with lung cancer.22   Furthermore, 
PGA-PTX has not been reported to self-assemble into 
nanoparticles. In our study, a new nanoconjugate   platform, 
  PGG-PTX, was designed and synthesized without   utilizing 
diblock copolymers. We reasoned that in the case of 
  PGA-PTX, PTX molecules attached directly to the PGA 
precluding the   flexibility needed for the polymer conjugate International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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collapse and for the formation of a nanoparticle. In the case 
of PGG-PTX, the PGA was first modified by adding another 
glutamic acid as a side chain to each glutamic acid in the 
polymer backbone. The PTX was then covalently conjugated 
to the added glutamic acid side chain. The glutamic acid 
linker was found to provide additional water-solubility so that 
the polymer could be loaded to a high level with PTX while 
having sufficient flexibility through which the hydrophobic 
PTX moieties could interact and cause the polymer to form 
a nanoparticle.
PGG-PTX was synthesized in three steps, as shown in 
  Figure 1, from commercially available PGA sodium salt with a 
Mw of 24,880 Da as determined by GPC-MALS. When work-
ing with polymer–drug conjugates, choosing the right reagents 
and solvents is a major determinant of success in achieving 
the final pure product. In this synthesis, only water-soluble 
reagents and solvents were used for the ease of purification 
and isolation by precipitation, filtration, and dialysis.
The first goal was to obtain PGG. The synthesis began with 
poly-L-glutamate coupled to 2.2 equivalence of L-  glutamic 
acid di-tert-butyl ester hydrochloride using coupling agents 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide and 
1-hydroxybenzotriazole; the reaction mixture was stirred at 
room temperature for 24 hours and yielded an intermediate 
PGG-tBu ester, which was easily purified by precipitation in 
a large volume of water and filtered through a Buchner fun-
nel. PGG-tBu ester was further treated with trifluoroacetic 
acid to convert it to PGG (Mw 53,180 Da, yield 87%). The 
1H-NMR spectrum showed chemical shifts at δ 4.40 (broad, 
1 H), 4.22 (broad, 1 H), 2.45 (broad, 4 H), 2.15 (broad, 3 H), 
and 1.97 (broad, 1 H) ppm, which were consistent with the 
expected proton patterns and chemical shifts. The   conversion 
of PGA to PGG was complete, which was confirmed by 
1H-NMR integration 1:1 ratio of peaks δ 4.40 (broad, 1 H) 
and 4.22 (broad, 1 H; Supporting information). The   chemistry 
was found to be robust, and PGG can be produced at the 
10–15 g scale.
PTX was conjugated to PGG using the coupling agent 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide in the 
presence of catalytic amounts of 4-dimethylaminopyridine 
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Figure 1 Synthesis of PGG-PTX nanoconjugate.
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summaries Mws, refractive index increment (dn/dc), and 
polydispersity (Mw/Mn) for PGA, PGG, and PGG-PTX, 
respectively. The average Mw of   PGG-PTX was found to 
be 130,000 Da, with polydispersity index (Mw/Mn) of 1.87. 
PGG-PTX was found to be very pure as determined by 
SEC-HPLC as shown in Figure 2c.   Interestingly, PGG-PTX 
formed nanoparticles in   aqueous solutions. The particle size 
determined using Malvern   Zetasizer Nano-ZS dynamic 
light scattering method was found to be about 12–15 nm 
in saline in a range of concentrations from 2 mg/mL down 
to 0.025 mg/mL. Figure 3 shows that the critical micellar 
concentration of PGG-PTX in saline was determined to 
be about 25 µg/mL in 0.9% NaCl at ambient temperature. 
Due to its unique formation of nanoparticles, PGG-PTX 
is expected to efficiently target hypervascular tumors that 
have defective vascular architecture and impaired lymphatic 
drainage.
Comparison of polymer-PTX conjugates 
and their solubilities
PTX25 is a hydrophobic anticancer drug that is used for 
the treatment of many common cancers. Because of its 
hydrophobicity, it is formulated in the solubilizing agent 
Cremophor, which can produce a variety of adverse 
events.14 Up to now, PGA was considered to be the most 
water-soluble and commercially available polymer and has 
been used to create a PGA-PTX (CT-2103, Xyotax™; Cell 
Therapeautics Inc; Seattle, WA]) that has now been tested 
in several mouse models6 and human clinical trials.19–22 
The characteristics of PGG-PTX were compared with the 
information on the solubility and therapeutic efficacy of 
CT-2103. To determine this experimentally, PGG-PTX and 
PGA-PTX were synthesized. The PTX content of PGG-
PTX and PGA-PTX was determined by UV absorbance at 
228 nm and was found to be 35% and 33%, respectively. 
It is important to note that PGG is about twice the size of 
PGA due to the addition of a glutamate side chain on each 
glutamyl in the polymer backbone. The addition of another 
glutamate side chain was confirmed by 1H-NMR analysis of 
PGG, wherein ratio of integration of the α proton (δ 4.19 
ppm) of the PGA backbone to the glutamate side chain 
(δ 4.40 ppm) is 1:1 (see Supporting information). Thus, 
when loaded to 35% with PTX, the PGG-PTX contained 
about twice as much PTX as the PGA-PTX. The solubility 
of the conjugates was compared in 0.9% NaCl at a con-
centration of 50 mg/mL. Although PGG-PTX dissolved 
completely within 20 minutes, the   PGA-PTX dissolved only 
partially, and most of the PGA-PTX remained in suspension 
to produce PGG-PTX. The reaction was monitored using 
TLC with ethyl acetate (Rf of PTX is around 0.8). PTX was 
completely conjugated to PGG after 20 hours of   stirring at 
room temperature; TLC showed that there was an absence 
of a spot of Rf around 0.8. The PTX is expected to be ran-
domly   distributed along the PGG polymer and attached 
predominantly at the 2′-O-position of PTX, with a minor 
amount linked via the 7-O position based on a single-mol-
ecule chemistry model of a variety of amino acids coupled 
to PTX.23 Furthermore, in PGG, two carboxyl groups are 
capable of conjugating with the 2′-hydroxyl and 7-hydroxyl 
group of the PTX. As a result, 1H-NMR spectrum could 
not provide resolvable chemical shifts of the PGG-PTX; 
however, it could be confirmed that the aromatic protons 
of the PTX were observed (see Supporting information). 
The PTX   content of PGG-PTX was estimated using another 
established method6 and was found to be 35.8% based on 
a standard curve generated with known concentrations 
of PTX in methanol (A = 228 nm) with an R2 value of 
0.9999. The chemistry for the coupling of PTX to PGG is 
also very robust and it is possible to produce PGG-PTX at 
the 10–15 g scale. Conjugation using the dicyclohexylcar-
bodiimide coupling agent was also investigated; however, 
under the conditions needed for dicyclohexylcarbodiimide 
coupling, it was not possible to isolate a pure product due 
to the side product, dicyclohexylurea, being trapped within 
PGG-PTX.
Characterization of PGG-PTX
The characterization of PGG-PTX was complicated by the 
extent of interaction of the conjugate with itself and with 
the column. The Mw of PGG-PTX was characterized by 
(GPC-MALS) detection.24 With phosphate-buffered saline 
as the mobile phase; the recovery was ∼25% due to the high 
binding affinity of the conjugate to the columns. Increasing 
the methanol concentration from 20% to 40% progressively 
reduced the binding affinity and the tailing effect. The 
recovery increased from 25% to 90%; the light-scattering 
signal was more symmetrical at 40% methanol. Increas-
ing the methanol concentration from 40% to 60% did not 
significantly affect the Mw, recovery percentage, or further 
affect the symmetrical light-scattering signal of the PGG-
PTX. Based on these findings, phosphate-buffered saline 
containing 45% methanol was chosen as the mobile phase 
for GPC-MALS and SEC-HPLC. Since PGA and PGG did 
not exhibit high affinity for the column, phosphate-buffered 
saline containing 30% methanol was used as the mobile 
phase for these two   nondrug-loaded polymers. Table 1 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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as shown in Figure 4. In order to get PGA-PTX dissolved 
completely, the concentration had to be lowered to 7 mg/
mL or the duration of dissolution increased to .10 hours. 
Thus, the experimental data confirmed the hypothesis that 
the addition of a glutamic acid linker would substantially 
increase the water-solubility of the PTX-loaded polymer. 
Furthermore, PGG is highly water-soluble; even in the acid 
form, it can dissolve readily in water, whereas PGA cannot. 
PGG can potentially be used to deliver other hydrophobic 
drugs such as camptothecin and doxorubicin. Because of 
the bidentate ligand of the extra glutamic acid, it may also 
be capable of chelating cisplatin.
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Figure 2 SEC-HLPC chromatograms of PGA, PGG, and PGG-PTX. The chromatograms were recorded at 228 nm. A) PGA; B) PGG; C) PGG-PTX.
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Biological evaluation  
of polymer-PTX conjugates
The cytotoxicity of PGG-PTX was compared with that of 
free PTX25 against human lung cancer H460 cells using a 
growth inhibition assay. As shown in Figure 5, free PTX was 
more potent than either of the polymer conjugates, whereas 
the 2 conjugates demonstrated equivalent half maximal inhibi-
tory concentration (IC50) values. The IC50 for PGG-PTX was 
2.31 ± .01 (standard error of mean [SEM]) µM, whereas that 
for PGA-PTX was 2.25 ± 0.02 (SEM) µM and that for PTX 
0.15 ± 0.02 (SEM) µM. Thus, in vitro, the conjugates were 
15-fold less potent than free PTX. The potency of PGG-PTX 
was comparable to other known polymer-PTX conjugates when 
tested in vitro against the human lung cancer H460 cell line.
To compare their toxicities in vivo, the maximum toler-
ated dose of each compound was determined in nu/nu mice 
for a single-dose schedule. PGG-PTX was dissolved in 0.9% 
NaCl at 50 mg/mL and administered by bolus intravenous 
injection through the tail vein. The maximum tolerated dose 
was defined as the dose that produced 15% loss of body 
weight within 2 weeks. The maximum tolerated single dose 
of PGG-PTX was found to be 350 mg PTX/kg, which is 2.2-
fold higher than the maximum tolerated dose of 160 mg PTX/
kg reported for the PGA-PTX CT-21036 and 4.4-fold higher 
AB
Figure 4 Photographs of a solution of A) PGG-PTX (35% PTX loading) and B) PGA-PTX (32% PTX loading) in saline (0.9% NaCl). The polymer-PTX conjugates were 
dissolved in 0.9% NaCl at 50 mg/mL after sonication for 1 minute and allowed to stand for 20 minutes.
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Figure 5 Inhibition of the growth of human lung cancer H460 cells as a function of concentration of PTX (O), PGA-PTX () and () PGG-PTX. 
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than the maximum tolerated dose of PTX in Cremophor 
(80 mg/kg).6 This result indicates that PGG-PTX was sub-
stantially less toxic in vivo than either free PTX or PGA-PTX. 
Studies of pharmacokinetics and biodistribution showed that 
PGG-PTX polymer significantly prolonged the half-life of 
total taxanes, extractable taxane, and native PTX in both the 
plasma and the tumor compartments.26 Furthermore, results 
of in vivo efficacy studies also showed that PGG-PTX has 
superior therapeutic activity to that of Abraxane in multiple 
tumor models.27
We have successfully designed and synthesized a new 
nanoconjugate platform for the delivery of hydrophobic anti-
cancer drug PTX. The particle size of PGG-PTX was about 
15 nm, and the size did not vary as the drug was diluted. The 
experimental data indicated that PGG-PTX was substantially 
more soluble than PGA-PTX despite the fact that the former 
contains approximately twice as much PTX per polymer as 
the latter. Importantly, using the PGG polymer, we were able 
to develop a PTX conjugate with much higher drug loading 
compared with CT-2103, the PGA-PTX currently in clinical 
development.
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Figure S7 PGG-PTX (50 µg/mL) in saline. Diameter = 14.7 nm; PDI = 0.599.
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Figure S6 PGG-PTX (2,000 µg/mL) in saline. Diameter = 13.7 nm; PDI = 0.404.